Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation, a US-based vaccines company, for approximately $2.2 billion. The move significantly strengthens Sanofi’s position in adult immunization.
The deal brings together Dynavax’s differentiated adult vaccines with Sanofi’s global scale and commercial reach.
It directly addresses major unmet needs in adult vaccination.
Key strategic benefits include:
A central asset in the acquisition is Heplisav-B, Dynavax’s marketed adult hepatitis B vaccine.
What makes it different:
This simplified dosing could improve compliance among adults who remain unvaccinated.
The transaction also includes Dynavax’s shingles vaccine candidate, Z-1018, currently in Phase 1/2 development. Additional early-stage vaccine programs are also part of the deal.
Together, these assets expand Sanofi’s long-term vaccines pipeline.
Adult immunization remains underpenetrated, especially in the US.
Key data points:
These gaps create a strong case for expanded adult vaccination strategies.
The Dynavax board has unanimously approved the transaction.
Sanofi sees the acquisition as a natural extension of its vaccine strategy. Dynavax believes Sanofi’s global infrastructure will maximize the impact of its vaccines.
Both companies emphasize evidence-based immunization and long-term public health impact.
This acquisition reinforces a clear trend. Large biopharma companies are doubling down on adult immunization as a growth and impact area.
For Sanofi, Dynavax adds:
If executed well, this deal could reshape Sanofi’s vaccines business for the next decade.